Trial Profile
A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs GC 1109 (Primary)
- Indications Anthrax
- Focus Pharmacodynamics
- Sponsors GC Biopharma
- 02 Jan 2023 Status changed from not yet recruiting to completed.
- 21 Jun 2021 Planned number of patients changed from 299 to 345.
- 21 Jun 2021 Planned End Date changed from 1 Nov 2016 to 1 Jan 2023.